I would like to thank them for their efforts for the patients whose lives are touched by Natus products every day. Over the past two months, I've had the opportunity to engage teammates throughout Natus and I have been impressed with the talent, experience and passion that they bring to our company. I consider it an honor and a privilege to lead this company. Today marks the completion of my ninth week with Natus Medical. Drew will then provide our financial guidance for the full-year 2022 and will turn it back to me for closing comments and Q&A. Following this, I will discuss our strategic review and the actions we are taking as a result. Following my brief introduction, Drew will review the fourth quarter and full-year 2021 financial results. On page 3 of the presentation, you will find the agenda for today's call. Drew and I will refer to the presentation throughout our comments. A copy of today's investor deck is available on the Investors Relations page of the Natus website I am joined on today's call by our Executive Vice President and Chief Financial Officer, Drew Davies. Thank you for investing your time to listen to our discussion of Natus' fourth quarter 2021 financial results, as well as an investment presentation of Natus' strategic review and go-forward clinical focus and business model. Sullivan, President and Chief Executive Officer of Natus Medical. I would now like to turn the call over to Mr. You can find a reconciliation of financial results on a GAAP versus non-GAAP basis in yesterday's earnings release. Management believes that the presentation of these non-GAAP measures, along with our GAAP financial statements, provide a more thorough analysis of our ongoing financial performance. The non-GAAP results exclude amortization expense, restructurings and certain other charges and their related tax effects. Management's presentation of the financial results will be on a GAAP and non-GAAP basis. For a description of relevant risk and uncertainties pertaining to our business, please see yesterday's press release and our periodic and annual reports filed with the SEC. Our actual results may differ materially from these forward-looking statements. These statements include management's beliefs and expectations about our future results. Today's call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Drew will discuss the fourth quarter financial performance and 2022 guidance. Sullivan will provide a brief overview of the fourth quarter 2021 and discuss the strategic direction of Natus. Sullivan, Natus' President and Chief Executive Officer, and Drew Davies, Natus' Executive Vice President and Chief Financial Officer. On the call today from Natus is Thomas J. Good morning, everyone, and thank you for joining us today to review our Results for the Fourth Quarter of 2021. Thomas Sullivan - President and Chief Executive Officerĭrew Davies - Executive Vice President and Chief Financial Officer Natus Medical Incorporated ( NASDAQ: NTUS) Q4 2021 Results Earnings Conference Call Febru8:00 AM ET
0 kommentar(er)
